PTG Poltreg S.A.

4.549USD18.30 PLN · GPW0.00%Mkt Cap: 26.92M USDP/E: —

Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1…